Overview

Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to better understand mental illness and will test the hypotheses that while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after lorazepam. This study will enroll participants between the ages of 16 and 60, who have a psychotic illness (such as schizophrenia, bipolar disorder, and schizoaffective disorder). The study will also enroll eligible participants without any psychiatric illness, to compare their brains. The study will require participants to have 3-4 sessions over a few weeks. The first session (may be over two visits) will include a diagnostic interview and several questionnaires (qols) to assess eligibility. Subsequently, there will will be two separate functional magnetic resonance imaging (fMRI) sessions in which lorazepam or placebo will be given prior to the MRI. During the fMRI the participants will also be asked to answer questions. Additionally, the participants will have their blood drawn, women of child bearing potential will have a urine pregnancy test, vital signs taken, and asked to complete more qols.
Phase:
Phase 4
Details
Lead Sponsor:
University of Michigan
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
gamma-Aminobutyric Acid
Lorazepam